The Centre for Drug Development portfolio

Biologics

Agent (Trial)	Target or technology	Partnerships	Indications	Phase
ALETA001	Protein CD19, CD20	Aleta Biotherapeutics	Lymphoma	Phase 1

ASTVAC2	Vaccine LAMP, hTERT	Lineage Cell Therapeutics	Lung	Phase 1

Atezolizumab (DETERMINE )	Antibody PDL1	University of Manchester and Roche	Rare paediatric, teenage and young adult, and adult cancer	Phase 2

Trastuzumab + Pertuzumab (DETERMINE)	Antibody combination HER2	University of Manchester and Roche	Rare paediatric, teenage and young adult, and  adult cancer	Phase 2

Ginisortamab (UCB6114)	Antibody Gremlin1	UCB	Pancreatic	Phase 2

HMBD001	Antibody HER3	Hummingbird Bioscience	HER3 positive solid tumours, prostate	Phase 1/2

KJ103	Antibody TROP2	KisoJi Biotechnology	Solid tumours	Exploratory

MOv18 IgE	Antibody α-folate R	King's College London	Solid tumours	Phase 1

NVG222	BITE ROR1, CD3	NovalGen	Haematological	Preclinical

UCB4594	Antibody HLA-G1	UCB	Solid tumours	Phase 1

VTP-600 (MAGE)	Vaccine MAGE3, NY-ESO-1	Barinthus Biotechnology and Ludwig Institute for Cancer Research	Lung	Phase 1/2

Agent (Trial)	Target	Partnerships	Indications	Phase
Alectinib (DETERMINE)	ALK, TK1	University of Manchester and Roche	Rare paediatric, teenage and young adult, and adult cancers	Phase 2

Capmatinib (DETERMINE)	CMET, HGFR	University of Manchester and   Roche	Rare adult cancer	Phase 2

Entrectinib (DETERMINE)	ROS1, TLK, ALK	University of Manchester and Roche	Rare paediatric, teenage and young adult, and adult cancers	Phase 2

Vemurafenib + cobimetinib (DETERMINE)	BRAF, MAP, MEK	University of Manchester and Roche	Rare adult cancers	Phase 2

BT1718	MT1-MMP	Bicycle Therapeutics	Lung	Phase 1/2

HTL0039732	EP4	Nxera	Solid tumours	Phase 1/2

LY3143921	Cdc7	Lilly	Solid tumours	Phase 1/2

TT702 (CURATE)	Adenosine, A2BR	Teon Therapeutics	Solid tumours	Phase 1/2